Inhibrx Biosciences, Inc. (INBX)

NASDAQ:
INBX
| Latest update: Mar 11, 2026, 10:39 AM

Price Chart

$71.63

0.32%
(1 month)

Top Shareholders

Perceptive Advisors LLC
9.99%
Viking Global Investors LP
9.89%
Morgan Stanley
8.03%
Sanofi
7.96%
Hightower Holding LLC
5.99%
BlackRock, Inc.
5.35%
The Vanguard Group, Inc.
4.28%
Sofinnova Investments, Inc.
3.13%

Sentiment for INBX

News
Social

Buzz Talk for INBX

Today

Social Media

General

Stock events for Inhibrx Biosciences, Inc. (INBX)

In the past six months, Inhibrx Biosciences, Inc. stock has experienced a substantial increase of 512.94% between February 27, 2025, and February 26, 2026. In October 2025, positive topline results were announced from the ChonDRAgon study for ozekibart (INBRX-109). In November 2025, the company reported its third-quarter 2025 financial results. In December 2025, updates were provided on the INBRX-106 program and ozekibart expansion cohorts. Also in December 2025, Citizens reiterated a "Market Perform" rating, citing concerns about limited data disclosures and a lack of management communication.

Demand Seasonality affecting Inhibrx Biosciences, Inc.’s stock price

There is no specific information available regarding demand seasonality for Inhibrx Biosciences, Inc.'s products or services, as it is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates that are not yet commercially available.

Overview of Inhibrx Biosciences, Inc.’s business

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutics for life-threatening conditions. The company operates in the Biotechnology and Medical Research industry, utilizing proprietary modular protein engineering platforms. Its clinical pipeline includes Ozekibart (INBRX-109), a tetravalent therapeutic candidate targeting DR5, being investigated for chondrosarcoma, metastatic colorectal cancer, and Ewing sarcoma. INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4, is being developed for various metastatic solid tumors. INBRX-101, a protein therapeutic for alpha-1 antitrypsin deficiency, was acquired by Sanofi in May 2024.

INBX’s Geographic footprint

Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. Its primary operations and clinical trials are conducted within the United States.

INBX Corporate Image Assessment

Inhibrx Biosciences' brand reputation has been influenced by positive clinical advancements and analyst concerns. The positive topline results from the ChonDRAgon study for ozekibart (INBRX-109) enhanced the company's scientific and clinical reputation. However, an analyst from Citizens reiterated a "Market Perform" rating, expressing concerns about limited data disclosures and lack of management communication.

Ownership

Inhibrx Biosciences, Inc. has a mixed ownership structure, with approximately 82.46% of the stock held by institutions and 17.09% held by insiders. Major institutional owners include Perceptive Advisors Llc, Viking Global Investors Lp, Morgan Stanley, Sanofi, HighTower Advisors, LLC, BlackRock, Inc., Vanguard Group Inc, Sofinnova Investments, Inc., Capital Research Global Investors and State Street Corp.

FAQ

What is the current stock price of Inhibrx Biosciences, Inc.?

As of the latest update, Inhibrx Biosciences, Inc.'s stock is trading at $71.63 per share.

What’s happening with Inhibrx Biosciences, Inc. stock today?

Today, Inhibrx Biosciences, Inc. stock is down by -0.32%, possibly due to news.

What is the market sentiment around Inhibrx Biosciences, Inc. stock?

Current sentiment around Inhibrx Biosciences, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Inhibrx Biosciences, Inc.'s stock price growing?

Over the past month, Inhibrx Biosciences, Inc.'s stock price has decreased by -0.32%.

How can I buy Inhibrx Biosciences, Inc. stock?

You can buy Inhibrx Biosciences, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol INBX

Who are the major shareholders of Inhibrx Biosciences, Inc. stock?

Major shareholders of Inhibrx Biosciences, Inc. include institutions such as Perceptive Advisors LLC (9.99%), Viking Global Investors LP (9.89%), Morgan Stanley (8.03%) ... , according to the latest filings.